Merck Won't Yield on Yield
Merck still gets high marks from credit-rating firms. At Moody's Investors Service, for example, Merck ranks No. 4 among 21 drug companies. Moody's looks at many factors to develop its credit ratings, and Merck's free-cash-to-debt ratio is still in the high-grade range, says the agency's Michael Levesque. The operating-cash-to-debt ratio, which excludes dividends, still qualifies for a top rating, he says.
Levesque says Merck's "Aa3" rating should hold this year and next as long as the company can generate $1.5 billion in free cash flow annually and keep the Vioxx liabilities under $10 billion. The key to the near-term rating is the Vioxx litigation, Levesque says.
Another type of lawsuit is weighing on the dividend strategy at Bristol-Myers Squibb (BMY), which has the highest yield among its peers and a weaker credit rating than Merck. Like Merck, it suffers from too many big-revenue drugs losing, or about to lose, patent protection, and few promising replacements on the horizon.
Bristol-Myers is awaiting a trial challenging its U.S. patent for its biggest drug, the anticoagulant Plavix. A court date has been set for April 2006. The company and its partner Sanofi-Aventis (SNY) are fighting two generic drugmakers that are trying to invalidate a patent that runs into 2011."An adverse outcome would cause us to re-evaluate operational and financial needs, including the dividend," says Jeffrey Schoenborn, a Bristol-Myers spokesman, whose company is developing contingency plans for a Plavix ruling. Plavix produced $980 million in third-quarter sales, or 20% of corporate revenue. The quarterly payout is 28 cents a share, a level it has held for four years. Meanwhile, Bristol-Myers remains in the Wall Street doghouse, as only one out of 25 analysts who cover it has a buy rating, according to Thomson First Call. Litigation made Wyeth (WYE) face a dividend decision in the late 1990s and early 2000s because of legal liabilities related to the diet drugs Pondimin and Redux, which were withdrawn from the market in 1997.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV